PreMD's New LungAlert(TM) Test Format Presented at the 2006 AACC Annual Meeting
July 27 2006 - 10:00AM
PR Newswire (US)
TORONTO, July 27 /PRNewswire-FirstCall/ -- PreMD Inc.'s (TSX: PMD;
Amex: PME) new, patent-pending test format for LungAlert(TM) can be
easily processed using standard, automated laboratory equipment,
according to data presented today at the American Association for
Clinical Chemistry Annual Meeting in Chicago, Illinois. LungAlert
is a non-invasive test that detects a cancer-associated sugar in a
sputum (phlegm) sample. The patient produces the sputum by coughing
into a cup. The sample is treated with PreMD's proprietary test,
which produces a color change reaction that is read with a
spectrophotometer, or color reader, to quantify the results. "This
new, microwell-based format is designed for rapid processing in an
automated, high volume laboratory environment, which should help to
increase LungAlert's market appeal and broaden opportunities for
the technology," said Dr. Michael Evelegh, Executive Vice
President, Clinical and Regulatory Affairs of PreMD. "The microwell
method could also be applied in the diagnosis of other cancers from
which fluids or mucus secretions can be obtained, such as breast,
colorectal, cervical and prostate cancers." The abstract presented
by Dr. Evelegh was A Microwell-Based Galactose Oxidase-Schiff's
Assay for Thomsen-Friedenreich Antigen in Diagnosis of Lung Cancer,
authored by G. Cox and J. Miller, of McMaster University, Hamilton,
Ontario, and R. Zawydiwski, M. Evelegh and C. Carte, of PreMD. The
abstract is available online at http://www.premdinc.com/, in the
Clinical Research section. The AACC is an international
scientific/medical society that provides leadership in advancing
the practice and profession of clinical laboratory medicine and its
role in improving health care. About PreMD PreMD Inc. is a world
leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products, which are branded as
PREVU(x) Skin Sterol Test, are licensed worldwide to McNeil
Consumer Healthcare. The company's cancer tests include
ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's
head office is located in Toronto, and its research and product
development facility is at McMaster University in Hamilton,
Ontario. For further information, please visit
http://www.premdinc.com/. This press release contains
forward-looking statements. These statements involve known and
unknown risks and uncertainties, which could cause the Company's
actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the successful development or marketing of the
Company's products, the competitiveness of the Company's products
if successfully commercialized, the lack of operating profit and
availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of
the Company to take advantage of business opportunities,
uncertainties related to the regulatory process, and general
changes in economic conditions. In addition, while the Company
routinely obtains patents for its products and technology, the
protection offered by the Company's patents and patent applications
may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain
patent protection for our products or product candidates. Investors
should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. PreMD is providing this information as
of the date of this press release and does not undertake any
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise. (x) Trademark DATASOURCE: PreMD Inc. CONTACT: Ron
Hosking, Chief Financial Officer, Tel: (416) 222-3449, Email: ;
Sarah Borg-Olivier, Director, Communications, Tel: (416) 222-3449,
Email:
Copyright